Israeli acute heart failure (HF) therapy firm Magenta Medical Ltd. has bulked up its coffers with an additional $15m, following a Series B financing that brought in new investors from Japan and the clinical cardiovascular community.
The latest injection of funds is nearly twice the $8.5m raised by the start-up in previous financing rounds, in which Israeli venture capital firm Pitango and Abiomed Inc., developer of the world's smallest heart pump Impella, were the key investors. These two parties also participated in the series B, together with JAFCO Co Ltd
In conjunction with this financing, Magenta has also appointed David Israeli as its CEO